Stifel Announces Pricing of $150 Million of Non-Cumulative

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stifel Announces Pricing of $150 Million of Non-Cumulative Perpetual Preferred Stock & $200 Million of Senior Notes

ST. LOUIS, MO --(Marketwired - July 11, 2016) - Stifel Financial Corp. ( NYSE : SF ) today announced it has priced an underwritten registered public offering of $150 million perpetual 6.25% Non-Cumulative Perpetual Preferred Stock, Series A, and the pricing of $200 million principal amount of the Company's 4.25% Senior Notes due 2024.

6.25% Non-Cumulative Perpetual Preferred Stock:

The Company has priced an underwritten registered public offering of 6,000,000 depositary shares, each representing a 1/1000th interest in a share of perpetual 6.25% Non-Cumulative Perpetual Preferred Stock, Series A, $1.00 par value, with a liquidation preference of $25,000 per share (equivalent to $25 liquidation preference per depositary share).

When, as, and if declared by the board of directors of the Company, dividends will be payable at an annual rate of 6.25%, payable quarterly, in arrears. The Company may redeem the Series A preferred stock at its option, subject to regulatory approval, on or after July 15, 2021 or following a regulatory capital treatment event as described in the prospectus supplement and accompanying prospectus relating to the offering.

Stifel expects to use the net proceeds from the offering for general corporate purposes. The offering is expected to close on July 15, 2016, subject to customary closing conditions.

Keefe, Bruyette & Woods, a Stifel Company , Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Morgan Stanley are acting as book-running managers.

This offering will be made only by the prospectus and prospectus supplement related to this offering. Copies of the preliminary prospectus supplement and the accompanying base prospectus, when available, may be obtained from Keefe, Bruyette & Woods, a Stifel Company , Attn: Capital Markets, 787 Seventh Avenue, 4th Floor, New York, NY 10019, (800) 966-1559; Merrill Lynch, Pierce, Fenner & Smith Incorporated, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or by emailing: dg.prospectus_requests@baml.com ; or from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, New York, NY 10014.

4.25% Senior Notes:

The Company has also completed the pricing of an additional $200 million in aggregate principal amount of the Company's 4.25% Senior Notes due 2024 at a public offering price of 101.466% of the principal amount, plus accrued interest from January 18, 2016 (the "Notes"). The Notes constitute a further issuance of, rank equally in right of payment with, and form a single series with the $300 million in aggregate principal amount of the 4.25% Senior Notes due 2024 that the Company issued on July 18, 2014.

The Notes will be issued pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission on Form S-3 and available for review on the Securities and Exchange Commission's website at www.sec.gov .

The net proceeds from this offering will be used to repay the Company's outstanding 5.375% Senior Notes due 2022 and for other general corporate purposes, which may include the repayment of additional indebtedness.

The closing of the Notes offering is expected to occur on July 14, 2016, subject to certain customary conditions.

Keefe, Bruyette & Woods, a Stifel Company , Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Morgan Stanley are acting as book-running managers for the Notes. U.S. Bancorp is acting as co-manager for the Notes.

This offering will be made only by the prospectus and prospectus supplement related to this offering. Copies of the preliminary prospectus supplement and the accompanying base prospectus, when available, may be obtained from Keefe, Bruyette & Woods, a Stifel Company , Attn: Debt Capital Markets, 787 Seventh Avenue, 4th Floor, New York, NY 10019, (800) 966-1559; Merrill Lynch, Pierce, Fenner & Smith Incorporated, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or by emailing: dg.prospectus_requests@baml.com ; or from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, New York, NY 10014.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Stifel Company Information Stifel Financial Corp. ( NYSE : SF ) is a financial services holding company headquartered in St. Louis, Missouri that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel's broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated; Keefe Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Century Securities Associates, Inc., and in the United Kingdom and Europe through Stifel Nicolaus Europe Limited. The Company's broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank & Trust offers a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company's web site at www.stifel.com .

Cautionary Note Regarding Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are based upon our current expectations and projections about future events. We intend for these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of these safe harbor provisions. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the statements. In addition, our past results of operations do not necessarily indicate our future results. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include: the ability to successfully integrate acquired companies or the branch offices and financial advisors; a material adverse change in our financial condition; the risk of borrower, depositor and other customer attrition; a change in general business and economic conditions; changes in the interest rate environment, deposit flows, loan demand, real estate values and competition; changes in accounting principles, policies or guidelines; changes in legislation and regulation; other economic, competitive, governmental, regulatory, geopolitical and technological factors affecting our operations, pricing and services. Forward-looking statements speak only as to the date they are made. We do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. We disclaim any intent or obligation to update these forward-looking statements.

Stifel Investor Relations Joel Jeffrey (212) 271-3610 investorrelations@stifel.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 182

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 110

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 247

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 116

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 0

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 197

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

b1BANK Partners with Spiral to Enhance Community Banking Impact

Updated Category News Views 97

Enhanced Financial Wellness through Partnership NEW YORK--Today, Spiral, a personalized banking platform, announced a significant partnership with b1BANK, established as a community-focused banking institution. Through this collaboration, the two organizations aim to enhance financial wellness for customers, leveraging b1BANK's dedication to innovative banking solutions...

Continue Reading
AM Best Explores Trends Influencing For-Hire Trucking Industry

Updated Category News Views 168

Insights from AM Best's Latest Webinar on Trucking Trends Viewers can now delve into the highlights from the enlightening webinar hosted by AM Best, titled "For-Hire Trucking: The Risky Road Ahead." This event focused on the intricacies and challenges within the transportation-for-hire trucking sector, providing expert insights into risk management strategies and the...

Continue Reading
BitMart's Creative Campaign to Ignite Offline Crypto Engagement

Updated Category News Views 135

Introducing the Fox Hunt Delivery Campaign BitMart, a leading global cryptocurrency exchange, is excited to announce the launch of the Fox Hunt Delivery Campaign, a unique initiative aimed at boosting cryptocurrency adoption through engaging offline activities. This campaign offers an exciting chance for participants to earn USDT rewards simply by introducing new users to...

Continue Reading
Trinity Capital Inc. Fuels Alt Platform's Growth with $40M Credit

Updated Category News Views 273

Trinity Capital Inc. Supports Alt with Significant Credit Facility Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, is thrilled to announce a groundbreaking agreement with Alt, providing up to $40 million through an asset-based revolving credit facility. This funding aims to bolster Alt's innovative marketplace tailored for trading card...

Continue Reading
Everest Medicines Achieves Record Revenue and Growth in 2024

Updated Category News Views 506

Everest Medicines Achieves Remarkable Financial Success Everest Medicines, a groundbreaking biopharmaceutical company focused on innovative healthcare solutions, has reported remarkable financial results for the year ending December 31, 2024. With a robust revenue growth of 461%, the company stands out in the pharmaceutical industry, showcasing its resilience and dynamic...

Continue Reading